Interstitial pneumonitis associated with leuprorelin acetate for a prostate cancer: A case report.
J Oncol Pharm Pract
; 28(8): 1910-1913, 2022 Dec.
Article
en En
| MEDLINE
| ID: mdl-35234109
ABSTRACT
INTRODUCTION:
Androgen deprivation therapy remains the essential treatment for disseminated prostate cancer. Interstitial pneumonitis following this therapy has been documented for just a few cases. However, reported cases frequently describe the onset of symptoms after recent administration (days or a few weeks) of both GnRH analogues and androgen antagonists, which makes the precise individual impact of each treatment difficult to estimate. CASE REPORT This report presents a case of a 94-year-old patient with interstitial pneumonitis whose onset started three months after the first dose of leuprorelin and bicalutamide for a metastatic prostate cancer. MANAGEMENT ANDOUTCOME:
Once other possible diagnosis were ruled out, empiric corticosteroid treatment was initiated within 48 h of the admission. A spectacular clinical and radiological improvement was observed after 3 doses of steroids, enabling the patient to recover his basal respiratory situation. We considered that the most probable cause was toxic interstitial pneumonitis induced by leuprorelin.DISCUSSION:
To our knowledge, it describes the longest interval between last administration of antiandrogen therapy and the development of pneumonitis. This fact may support a direct relation with leuprorelin, whose serum levels remain high for months because of its long-acting depot formulation.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Enfermedades Pulmonares Intersticiales
Tipo de estudio:
Risk_factors_studies
Límite:
Aged80
/
Humans
/
Male
Idioma:
En
Revista:
J Oncol Pharm Pract
Asunto de la revista:
FARMACIA
Año:
2022
Tipo del documento:
Article
País de afiliación:
España